Aims & Scope
Human Antibodies is an international journal designed to bring together all aspects of human hybridomas and antibody technology, along with factors that modulate host antibody repertoire and effectiveness, such as vaccines, infectious agents, and microbiome. This includes fundamental research, applied science and clinical applications. Emphasis in the published articles is on antisera, monoclonal antibodies, fusion partners, EBV transformation, transfections, in vitro immunization, defined antigens, tissue reactivity, scale-up production, chimeric antibodies, autoimmunity, natural antibodies/immune response, anti-idiotypes, and hybridomas secreting interesting growth factors. Immunoregulatory molecules, including T cell hybridomas, will also be featured.
Mark C. Glassy, PhD
UC San Diego
Moores Cancer Center
Translational Neuro-Oncology Laboratory
La Jolla, CA
Tel.: +1 858 566 9490
Robert M. Anthony, PhD
Massachusetts General Hospital, Center for Immunology & Inflammatory Diseases, Boston
Dimitrios P. Bogdanos, MBA, MD, PhD
University of Thessaly, Department of Rheumatology and Clinical Immunology, Thessaly
Dennis R. Burton, PhD
The Scripps Research Institute, Department of Immunology & Microbial Science - IMM2, La Jolla
Paul J. Carter, PhD
Genentech, Inc., Department of Antibody Engineering, San Francisco
Ricard Cervera, MD, PhD, FRCP
University of Barcelona
Department of Autoimmune Diseases at Hospital Clínic
Stefan Dübel, PhD
Technische Universitat Braunschweig, Braunschweig
Gilad Halpert, PhD
Sheba Medical Center, Zabludowicz Center for Autoimmune Diseases, Tel-Hashomer
Michael Hust, PhD
Technische Universität Braunschweig, Institut für Biochemie, Biotechnologie und Bioinformatik, Braunschweig
Angray S. Kang, BSc (Hons), PhD
Queen Mary University of London, Centre for Oral Immunobiology and Regenerative Medicine, Bart's and London Medical and Dental School, London
Renate Kunert, PhD
Universität für Bodenkultur, Department of Biotechnology, Vienna
Alois B. Lang, PhD
GeNeuro SA, Geneva
James W Larrick, MD, PhD
Regenerative Sciences Institute, Sunnyvale
Julian Ma, FDS RCS(Ed), PhD
Institute for Infection and Immunity, St. Georges University of London, London
James D. Marks, MD, PhD
San Francisco General Hospital, Department of Anesthesia, San Francisco
Sherie L. Morrison, PhD
UCLA, Department of Microbiology, Immunology and Molecular Genetics, Los Angeles
David Naor, PhD
The Hebrew University of Jerusalem, Faculty of Medicine, The Lautenberg Center of Immunology and Cancer Research, Jerusalem
Carlo Perricone, MD, PhD
University of Perugia, Department of Medicine and Surgery, Perugia
Andreas A. Plückthun, PhD
University of Zurich, Department of Biochemistry, Zurich
Matthew D. Scharff, PhD
Albert Einstein College of Medicine, Department of Cell Biology, Bronx, USA
Yehuda Shoenfeld, MD., FRCP, MaACR
Sheba Medical Center, Zabludowicz Center for Autoimmune Diseases, Tel-Hashomer
Sachdev Sidhu, PhD
University of Toronto, The Donnelly Centre, Toronto
Lim Theam Soon, PhD
Institute for Research in Molecular Medicine, Universiti Sains Malaysia, Penang
Jamie B. Spangler, PhD
Johns Hopkins University
Departments of Biomedical and Chemical & Biomolecular Engineering, Baltimore
Leonidas Stamatatos, PhD
Fred Hutchinson Cancer Research Center, Vaccine and Infectious Disease Division, Seattle
Michael Steinitz, PhD
The Hebrew University, Department of Pathology, Jerusalem, Israel
Mohammad Taheri, PhD
Institute of Human Genetics, Jena University Hospital, Jena
Jean-Luc Teillaud, PhD
French Institute of Health and Medical Research (INSERM), Paris
Louis M. Weiner, MD
Georgetown Lombardi Comprehensive Cancer Center, Department of Oncology, Washington
Gregory Winter, PhD
Trinity College, Cambridge
K. Dane Wittrup, PhD
Massachusetts Institute of Technology, Department of Chemical Engineering and Biological Engineering, Cambridge
Susan Zolla-Pazner, PhD
Icahn School of Medicine at Mount Sinai, Departments of Medicine (Division of Infectious Diseases) and Microbiology, New York
Cabell's Guide or Directory
Cambridge Scientific Abstracts
Chemical Abstracts Service (CAS)
INIST - Institute for Scientific and Technical Information
Ulrich's Periodicals Directory
Web of Science: Biological Abstracts
Web of Science: BIOSIS Previews
By default, articles published in Human Antibodies are available only to institutions and individuals with access rights. However, the journal offers all authors the option to purchase open access publication for their article as part of the IOS Press Open Library. This means that the final published version will be freely available to anyone worldwide, indefinitely, under a Creative Commons license and without the need to purchase access to the article. This is also referred to as “gold” open access.
Gold open access pricing
Authors who choose gold open access publication will be subject to an article publication charge of € 1500 / US$ 1500 for publication under the CC BY-NC 4.0 license or € 2150 / US$ 2150 for publication under the CC BY 4.0 license. Pricing is exclusive of possible taxes. After an article is accepted for publication, the corresponding author will be informed regarding the open access option during the production stages, and will have the opportunity to purchase open access for their article. It could be that the open access fee of an article is waived completely due an institutional agreement IOS Press has with the corresponding authors' institution. Please check the institutional agreements page for details.
Green open access
Authors who do not make use of the gold open access option may still make their article freely available using self-archiving, also referred to as green open access. Authors may make their final accepted manuscript available for free download from their personal or institutional website or institutional archive. This model is free for the author.
This journal deposits all open access articles in PubMedCentral (PMC) as part of the IOS Press Open Library. If an author chooses to publish their paper with open access then the publisher will deposit the article in PMC upon publication.
Peer Review Policy
Human Antibodies is a peer-reviewed journal. Articles submitted to the journal undergo a single blind peer review process. This means that the identity of the authors is known to the reviewers but the identity of the reviewers is not communicated to the authors. Please visit our reviewer guidelines for further information about how to conduct a review.
After automatic plagiarism screening through iThenticate, all submitted manuscripts are subjected to initial appraisal by the Editor-in-Chief and, if found suitable for further consideration, to rigorous peer review by independent, anonymous expert referees. Reasons to reject a paper in the pre-screening process could for example be because the work does not fall within the aims and scope, the writing is of poor quality, the instructions to authors were not followed or the presented work is not novel.
Papers deemed suitable to the journal will be forwarded to two reviewers. Reviewers are asked to excuse themselves from reviewing a submission if a conflict makes them unable to make an impartial scientific judgment or evaluation. Conflicts of interest include but are not limited to: collaboration with the authors in the past three years; any professional or financial affiliations that may be perceived as a conflict of interest; a history of personal differences with the author(s). The Editor-in-Chief strives to ensure a typical turnaround time of 3 months.
Reviewers are asked to judge a paper on at least:
- Significance to field
- Relevance to journal
- Data analysis
- Literature review
- Writing style/clarity
Based on the received reviews the Editor-in-Chief will write a decision letter:
- Minor revisions required
- Major revisions required
- Revise and resubmit
They mean the following:
- The manuscript is suitable for publication and only requires minor polishing; thus, no further reviews are requested.
- The authors are required to make moderate changes to their manuscript. The manuscript becomes acceptable for publication if the changes proposed by the reviewers and editors are successfully addressed. The revised manuscript will be examined by the Editor-in-Chief and possibly sent back to all (or a selection of) reviewers for a second round of reviews. Authors are requested to provide a letter to the reviewers detailing the improvements made for the resubmission.
- The manuscript cannot be accepted for publication in its current form. However, a major revision addressing all issues raised by the reviewers may be acceptable for publication. The revised manuscript will undergo a full second round of review. Authors are requested to provide a letter to the reviewers detailing the improvements made for the resubmission.
- In its current form, the manuscript is not suitable for publication. A resubmission would require substantial revisions and is only encouraged in special cases. The resubmitted manuscript will be considered as a new submission.
- The manuscript is rejected as it is deemed to be out of scope, not relevant, or not meeting the journal’s quality standards in terms of significance, novelty, and/or presentation.
Authors are notified by the Editor-in-Chief, whose decision is final.
Do you Wish to Receive Updates? – If you would like to receive news updates about our journal Human Antibodies (HAB), let us know by signing up at: tiny.cc/HABsignup. View the recent HAB mailing here.
Sustainable Development Goals
The content of this journal relates to SDG:
Visit the SDG page for more information.
Supporting Diversity and Inclusion
This journal supports IOS Press' actions relating to the Sustainable Development Goals (SDGs) and commits to the Diversity and Inclusion Statement.
More information will be available in due course. Check the SDGs page for updates.